Table 3.
Log-rank test and cox regression analysis of factors potentially related to overall survival
| Group A vs Group B | ||||
|
Log-rank test |
Cox regression |
|||
| Factors | n | P | HR (95%CI) | P |
| Treatment regimen | - | < 0.001 | - | - |
| EVBT-stenting-TACE-sorafenib | 37 | 0.18 (0.09-0.35) | < 0.001 | |
| TACE-sorafenib | 31 | 1 | - | |
| Type of tumor | 0.466 | - | - | |
| Nodular type | 59 | - | - | |
| Diffuse type | 9 | - | - | |
| HCC maximum diameter | - | 0.320 | - | - |
| ≥ 5 cm | 45 | - | - | |
| < 5 cm | 23 | - | - | |
| Child-pugh class | 0.298 | - | - | |
| A | 57 | - | - | |
| B | 11 | - | - | |
| ECOG performance status | - | 0.125 | - | - |
| 0 and 1 | 59 | - | - | |
| 2 | 9 | - | - | |
| Extrahepatic metastasis | - | 0.742 | - | - |
| Yes | 62 | - | - | |
| No | 6 | - | - | |
| Serum AFP level (ng/mL) | - | 0.586 | - | - |
| ≥ 400 | 37 | - | - | |
| < 400 | 31 | - | - | |
AFP: Alfa-fetoprotein; ECOG: Eastern cooperative oncology group; TACE: Transarterial chemoembolization.